ELF3 and Fabry disease: Two new forms of ERT, with increased stability and lower immunogenicity, for the treatment of Fabry disease have been developed; Pegunigalsidase-alfa (PRX-102, Protalix Biotherapeutics, Israel and Chiesi Global Rare Diseases, USA) and moss-agalactosidase A (moss-aGal, Greenovation biopharmaceuticals, Germany).